These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Deferasirox: for iron overload: only a third-line option. Journal: Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17929382. Abstract: In patients with iron overload, oral deferasirox has a less favourable risk-benefit balance than subcutaneous deferoxamine: deferasirox appears to be less effective and also has more hepatic and renal adverse effects. In second-line situations it is better to first use deferiprone (another oral treatment, with which deferasirox has not been compared), a drug with which we have more experience. However, as iron chelation can be a lifelong necessity for some patients, deferasirox can be reserved as a third-line option which may be useful in some cases.[Abstract] [Full Text] [Related] [New Search]